Stock Selection: Perplexity's picks for 2026-10-12
Perplexity picked CCI, MRNA, HUM, NVAX, FSLY for a 1-day horizon. Portfolio return vs SPY: -0.84%. Picks that beat SPY: 40%.
| Experiment | Stock Selection |
|---|---|
| Model | Perplexity |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-12 |
| Measured to | 2026-10-13 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -0.84% |
| Picks that beat SPY | 40% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CCI | +1.49% | 68% | +1.55% | Yes |
| 2 | MRNA | -4.83% | 63% | -4.77% | No |
| 3 | HUM | -3.43% | 62% | -3.37% | No |
| 4 | NVAX | -0.56% | 55% | -0.50% | No |
| 5 | FSLY | +2.84% | 52% | +2.90% | Yes |
The model's market view
US equities enter Monday with modestly positive futures, supported by cooling oil, strong expected bank earnings, and continued technology momentum; however, sticky inflation expectations and geopolitical oil risk cap conviction. I favor high-momentum names with fresh catalysts, especially healthcare and communications infrastructure, over broad beta.
Why each pick
CCI
Crown Castle surged 15.60% on Friday after SpaceX's 800 MHz spectrum deal highlighted potential tower-leasing demand. The stock closed at $79.64 on 2026-10-09 (most recent regular-session close; live intraday quote not available from the researched source), and strong volume plus a fresh thematic catalyst support follow-through. Risks: sharp mean reversion after a one-day spike, rate sensitivity as a REIT, and the stock remains below its 52-week high.
MRNA
Moderna rose 14.21% to a fresh 52-week high on NIH cancer-vaccine initiative attention and its Nasdaq-100 inclusion, closing at $225.00 on 2026-10-09 (most recent regular-session close; live intraday quote not available from the researched source). Index-related demand and oncology momentum may sustain relative strength. Risks: extreme valuation after a large rally, analyst skepticism including a Citi Sell rating, and binary clinical-data risk.
HUM
Humana advanced 11.56% after materially improved 2027 Medicare Advantage Star Ratings, with 95% of members in 4-star-or-higher plans, followed by multiple analyst upgrades and target increases. It closed at $431.87 on 2026-10-09 (most recent regular-session close; live intraday quote not available from the researched source). The catalyst is fundamental rather than purely speculative, supporting continuation. Risks: profit-taking after a large move, healthcare policy uncertainty, and a valuation near the consensus price target.
NVAX
Novavax gained 15.80% amid biotech enthusiasm tied to the NIH cancer-vaccine initiative, closing at $12.75 on 2026-10-09 (most recent regular-session close; live intraday quote not available from the researched source). High beta and sector momentum can produce further upside if healthcare speculation persists. Risks: very high volatility, weak standalone fundamentals, reliance on partnership milestones, and abrupt reversal risk in small-cap biotech.
FSLY
Fastly rose 15.86% to $29.30 on 2026-10-09 (most recent regular-session close; live intraday quote not available from the researched source), extending momentum around its AI-security product launches and edge-computing narrative. Strong revenue growth and improving margins provide a fundamental backdrop for continued speculative interest. Risks: the stock trades above the consensus price target, valuation is demanding, and high-momentum software names can retrace quickly if risk appetite weakens.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-6 | FSLR, CRM, CCC, CVX, IREN | -0.42% | 60% |
| Muse Spark 1.1 | CRM, FSLR, AMZN, MSFT, TSLA | +0.72% | 60% |
| Gemini 3 Pro | NVDA, MSFT, QQQ, AAPL, AMZN | +0.71% | 80% |
| Grok 4.5 | XLE, XOM, CRM, DHT, JPM | +1.16% | 80% |
| Claude Sonnet 5.5 | XOM, JPM, NVDA, CVX, XLU | +0.28% | 60% |
| DeepSeek | IREN, CCC, CRM, BIIB, FSLR | -1.00% | 40% |
Written up on ForecastNest Insights: Stock Selection: Perplexity's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.